AbCellera Biologics (ABCL) Change in Acquisitions & Divestments (2021 - 2026)

AbCellera Biologics' Change in Acquisitions & Divestments history runs 6 years deep, the most recent figure standing at $143.8 million for Q1 2026.

• Quarterly Change in Acquisitions & Divestments fell 24.33% year-over-year to $143.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $459.8 million (down 44.01% YoY) and the FY2025 annual result came in at $506.1 million, down 46.04% from the prior year.
• Change in Acquisitions & Divestments was $143.8 million for Q1 2026 at AbCellera Biologics, up from $119.5 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $306.5 million in Q1 2024 and bottomed at $57.3 million in Q1 2022.
• A 5-year average of $177.0 million and a median of $190.0 million in 2025 frame the typical range for Change in Acquisitions & Divestments.
• Annual changes were most pronounced in 2022 — Change in Acquisitions & Divestments jumped 410.99% — and 2025, when it sank 57.73%.
• AbCellera Biologics' Change in Acquisitions & Divestments stood at $92.4 million in 2022, then soared by 190.09% to $268.0 million in 2023, then slipped by 24.67% to $201.9 million in 2024, then tumbled by 40.79% to $119.5 million in 2025, then gained by 20.3% to $143.8 million in 2026.
• Business Quant data shows ABCL's Change in Acquisitions & Divestments at $143.8 million in Q1 2026, $119.5 million in Q4 2025, and $83.1 million in Q3 2025.